Paper Details

  1. Home
  2. Paper Details

Efficacy of oral tolvaptan in acute heart failure patients with hypotension and renal impairment.

Author: , BlairJohn, BurnettJohn C, GheorghiadeMihai, GrinfeldLiliana, KonstamMarvin A, KrasaHolly B, MaggioniAldo P, OuyangJohn, PangPeter S, SwedbergKarl, VaduganathanMuthiah, ZannadFaiez, ZimmerChristopher

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

This study investigated the short-term hemodynamic effects of tolvaptan in patients with acute heart failure, low blood pressure, and renal impairment.
Paper Details　
Original Abstract of the Article :
Although congestion is the main reason for admission in patients with worsening acute heart failure syndromes, patients presenting with low SBP and renal impairment often do not respond adequately to and may not tolerate traditional diuretic therapy. We sought to determine the short-term hemodynamic...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://pubmed.ncbi.nlm.nih.gov/22673023

データ提供：米国国立医学図書館（NLM）

Tolvaptan: A New Approach for Acute Heart Failure

Acute heart failure is a serious condition that can leave patients feeling lost in a desert of fear and uncertainty. This study investigates the potential of tolvaptan, a new drug, to treat acute heart failure patients with hypotension and renal impairment.

Tolvaptan: A Promising Therapy for High-Risk Patients

The research explores the short-term hemodynamic effects of tolvaptan in a high-risk population. It’s like finding a wellspring of hope in the desert of acute heart failure, offering a potential solution for patients who haven’t responded well to traditional treatments.

Hope for Improved Management of Acute Heart Failure

This research suggests that tolvaptan could be a valuable tool for managing acute heart failure in high-risk patients, potentially improving patient outcomes and quality of life.

Dr.Camel's Conclusion

The study on tolvaptan is like finding a hidden oasis in the desert of acute heart failure, offering a potential path to better treatment for high-risk patients. This promising therapy could bring a much-needed respite for those facing this challenging condition.

Date :
  1. Date Completed 2012-09-13
  2. Date Revised 2018-12-01
Further Info :

Pubmed ID

22673023

DOI: Digital Object Identifier

01244665-201207000-00001

Related Literature

Article Analysis
・Effects of tolvaptan (low blood sodium)
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.